• Je něco špatně v tomto záznamu ?

Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report

J. Kopecký, O. Kubeček, T. Geryk, B. Slováčková, P. Hoffmann, M. Žiaran, P. Priester,

. 2018 ; 12 (1) : 262. [pub] 20180915

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012378

BACKGROUND: Great progress has recently been made in the treatment of metastatic renal cell carcinoma, including the introduction of nivolumab, an immune checkpoint inhibitor. Despite promising results, this treatment brings a completely new spectrum of adverse events, distinct from those experienced with small-molecule kinase inhibitors. Neurologic immune-related adverse events may be serious and potentially life-threatening complications requiring immediate immunosuppressive therapy. Only a few cases of immune-related encephalitis induced by checkpoint inhibitors have been described and the data regarding the management of this serious adverse event are limited. CASE PRESENTATION: We report the case of a 63-year-old white man with metastatic renal cancer who developed severe chorea-like dyskinesia during nivolumab therapy. The findings on brain magnetic resonance imaging and flow cytometry of cerebrospinal fluid, and the positivity of anti-paraneoplastic antigen Ma2 immunoglobuline G class autoantibodies were consistent with a diagnosis of immune-related encephalitis. High-dose intravenous corticosteroid therapy was started immediately, with no signs of improvement, even when infliximab was added. Our patient refused further hospitalization and was discharged. Three weeks later, he presented with signs of severe urosepsis. Despite intensive treatment, he died 4 days after admission. CONCLUSIONS: The management of less frequent immune-related adverse events has not been fully established and more information is required to provide uniform recommendations. Immune-related encephalitis is a severe and potentially fatal complication requiring immediate hospital admission and extensive immunosuppressive therapy. The examination of cerebrospinal fluid for paraneoplastic antibodies, such as anti-N-methyl-D-aspartate receptor and anti-Ma2 antibodies, in order to distinguish autoimmune etiology from other possible causes is essential and highly recommended.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012378
003      
CZ-PrNML
005      
20190425105048.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13256-018-1786-9 $2 doi
035    __
$a (PubMed)30217214
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kopecký, Jindřich $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic. kopecjin@fnhk.cz.
245    10
$a Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report / $c J. Kopecký, O. Kubeček, T. Geryk, B. Slováčková, P. Hoffmann, M. Žiaran, P. Priester,
520    9_
$a BACKGROUND: Great progress has recently been made in the treatment of metastatic renal cell carcinoma, including the introduction of nivolumab, an immune checkpoint inhibitor. Despite promising results, this treatment brings a completely new spectrum of adverse events, distinct from those experienced with small-molecule kinase inhibitors. Neurologic immune-related adverse events may be serious and potentially life-threatening complications requiring immediate immunosuppressive therapy. Only a few cases of immune-related encephalitis induced by checkpoint inhibitors have been described and the data regarding the management of this serious adverse event are limited. CASE PRESENTATION: We report the case of a 63-year-old white man with metastatic renal cancer who developed severe chorea-like dyskinesia during nivolumab therapy. The findings on brain magnetic resonance imaging and flow cytometry of cerebrospinal fluid, and the positivity of anti-paraneoplastic antigen Ma2 immunoglobuline G class autoantibodies were consistent with a diagnosis of immune-related encephalitis. High-dose intravenous corticosteroid therapy was started immediately, with no signs of improvement, even when infliximab was added. Our patient refused further hospitalization and was discharged. Three weeks later, he presented with signs of severe urosepsis. Despite intensive treatment, he died 4 days after admission. CONCLUSIONS: The management of less frequent immune-related adverse events has not been fully established and more information is required to provide uniform recommendations. Immune-related encephalitis is a severe and potentially fatal complication requiring immediate hospital admission and extensive immunosuppressive therapy. The examination of cerebrospinal fluid for paraneoplastic antibodies, such as anti-N-methyl-D-aspartate receptor and anti-Ma2 antibodies, in order to distinguish autoimmune etiology from other possible causes is essential and highly recommended.
650    _2
$a protinádorové látky imunologicky aktivní $x škodlivé účinky $7 D000074322
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x sekundární $7 D002292
650    _2
$a encefalitida $x chemicky indukované $7 D004660
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nivolumab $x škodlivé účinky $7 D000077594
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubeček, Ondřej $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Geryk, Tomáš $7 xx0235124 $u Department of Fingerland Pathology, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Slováčková, Birgita $u Department of Psychiatry, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Hoffmann, Petr $u Department of Radiology, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Žiaran, Miroslav $7 xx0235093 $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Priester, Peter $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
773    0_
$w MED00184060 $t Journal of medical case reports $x 1752-1947 $g Roč. 12, č. 1 (2018), s. 262
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30217214 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190425105128 $b ABA008
999    __
$a ok $b bmc $g 1391688 $s 1050683
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 12 $c 1 $d 262 $e 20180915 $i 1752-1947 $m Journal of medical case reports $n J Med Case Reports $x MED00184060
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...